Introduction
============

The normal and pre-invasive human breast epithelium, which is the histological origin of over 80% of breast malignancies, is physically separated from the stroma by both the basement membrane and myoepithelial cells. The basement membrane is composed of type IV collagen, laminins, and other molecules, forming a continuous lining surrounding and attaching to myoepithelial cells [@B1]-[@B2]. Myoepithelial cells are joined by intercellular junctions and adhesion molecules, forming a continuous sheet that completely surrounds the normal duct system and a vast majority of the lobular units [@B3]-[@B4]. The predominant and phenotypic structural constituent of myoepithelial cells is microfilament, which could be elucidated by immunohistochemistry with a number of commercially available antibodies, including those to calponin, smooth muscle actin, smooth muscle myosin heavy chain, H-caldesmon, P-cadherin, and Cytokeratins 5, 7, 14, and 17 [@B5]. In H&E stained sections, myoepithelial cells are in cuboid or spindle shape with pale cytoplasm and nucleus. Under an electronic microscope, normal myoepithelial cells have a substantially fewer or no distinct rough reticulum endoplasm, Golgi complex, secretory granules, and a very low level of proliferating activities, compared to the associated epithelial cells [@B3]. Thus, myoepithelial cells have been traditionally regarded as an idle and passive physical barrier with no significant active functions [@B1]-[@B4].

Recent studies, however, have suggested that myoepithelial cells may possess a number of active functions. One of the functions is the production of tumor suppressers, including maspin, Wilms\' tumor 1 (WT-1), p63, and p73 [@B5]-[@B9]. *In vitro* and *in vivo* studies have shown that these tumor suppressors have significant paracrine inhibitory functions against tumor growth and invasion [@B5]-[@B9]. Our recent studies revealed that about 90% of morphologically distinct myoepithelial cells in normal and hyperplastic ducts had distinct expression of these tumor suppressors, whereas only about 70% of the myoepithelial cells in ducts with *in situ*breast cancer expressed these tumor suppressors [@B5],[@B9]. Our studies also revealed that a subset of normal, hyperplastic, and pre-invasive ducts and acini harbored focal disruptions (the absence of myoepithelial cells resulting a gap larger than a combined size of at least three myoepithelial cells) in their surrounding myoepithelial cell layers, and that a subset of morphologically distinct myoepithelial cells completely lacked the expression of all myoepithelial cell phenotypic markers [@B10]-[@B19]. Ducts and acini with focally disrupted myoepithelial cell layers or myoepithelial cell layers lacked expression of tumor suppressors had a significantly higher rate of cell proliferation, ER negativity, and expression of invasion related molecules than their morphologically similar counterparts with normal myoepithelial cell layers [@B10]-[@B19]. Together, these findings suggest that a reduction of tumor suppressor expression and focal disruption of the myoepithelial cell layers may significantly contribute to tumor aggressiveness and invasiveness.

Pregnancy-associated breast cancer (PABC) occurs during pregnancy or within one year of delivery. Although the incidence of PABC is low, it is the second most common cancer in pregnant women [@B20]-[@B23]. It has been well documented that a normal full-term of pregnancy is one of the most effective means of decreasing the lifetime-risk of breast cancer, whereas PABC is consistently associated with the most aggressive clinical course and highest mortality rate among breast malignancies [@B20]-[@B23]. These seemingly conflicting impacts have been largely attributed to proliferation and differentiation of stem cells, and remodeling of the cellular microenvironment and extracellular matrix [@B22]-[@B23]. The specific molecular or cellular mechanism, or unique molecules that are directly linked to aggressiveness and invasiveness, however, have not been identified. As the myoepithelial cell is the sole source of several tumor suppressors that have significant paracrine inhibitory function on tumor cell growth and invasion [@B5]-[@B9], our current study attempted to determine whether the myoepithelial cell layer of PABC would have aberrant tumor suppressor expression.

Materials and Methods
=====================

Formalin-fixed, paraffin-embedded tissue blocks from 20 patients with PABC, 20 cases of stage, grade, and age matched non-PABC, and 20 reduction mammoplasties of individuals with no family history of breast cancer, and no mammographic or histological breast abnormalities were selected from the cases sent to our institute for consultation with patients\' consent. All selected PABC and non-PABC cases contained normal, hyperplastic, *in situ*, or invasive components. Consecutive sections at 4-5 μm thickness were prepared and placed on positively charged slides. The first and last sections from each case were stained with hematoxylin and eosin (H&E) for morphological classification, based on our published criteria [@B24], which confirmed all the initial diagnosis.

Mouse monoclonal antibodies against human calponin (clone: CALP)), a most commonly used myoepithelial cell phenotypic marker, and maspin (clone: EAW24) were purchased from Novocastra Laboratories Ltd (Newcastle, UK). Mouse monoclonal antibodies against human WT-1 protein (clone: 6F-H2) and p63 protein (clone: 4A4) were purchased from Cell Marque (Hot Springs, AR). A mouse monoclonal antibody for proliferation marker Ki-67 (Clone: MM1) was purchased from DAKO (Capterria, CA). Mouse monoclonal antibodies against human estrogen receptor (ER; clone: ER-6F11) and progesterone receptor (PR; clone: PGR-312) were purchased from Novocastra Laboratories Ltd (Newcastle, UK). The secondary antibody, the ABC detection kit, and the DAB chromogen kit were purchased from Vector Laboratories (Burlingame, CA). A red chromogen, AP red, was purchased from Zymed Laboratories (South San Francico, CA). Sets of four adjacent sections were subjected to immunohistochemical staining using the protocol provided by the manufacturers.

To assess the specificity of the immunostaining, three technical approaches were used. First, different negative controls were used, which included (1) the substitution of the primary antibody with normal serum, (2) the omission of the secondary antibody from the immunostaining sequence, (3) serial dilutions of the primary antibody. Second, the same immunostaining protocol was used on the same cases, but substituting with different detection system and substrates. Third, the immunostaining procedure was repeated at least twice using the same protocol and under the same condition and immunostained sections were independently evaluated by at least two investigators. A given cell was considered immunoreactive to a given antibody when distinct immunoreactivities were consistently seen in either its cytoplasm nucleus, whereas all negative controls were devoid of distinct immunostaining.

To further confirm the specificity of calponin and WT-1 immunostaining, which occasionally cross-react with fiberoblasts and endothelial cells, a set of three adjacent sections from each case were subjected to immunohistochemical staining with molecular antibodies to cytokeratin (CK) 5 (clone: XM26), 14 (clone: LL002), and 17 (clone: E3; Novocastra Laboratories Ltd, Newcastle, UK), which are exclusively expressed in myoepithelial cells and cells with the epithelial origin.

From each case, 4-5 randomly selected duct and acinar clusters of each tissue component were photographed, and enlarged printers were made. As calponin is uniformly expressed in all or nearly all morphologically identifiable myoepithelial cells in H&E stained sections, the number of myoepithelial cells in a given duct or acinus was first determined in calponin stained sections. Using the obtained number as references, the number of positive and negative myoepithelial cells for each tumor suppressor in each duct or acinus was counted, and the numbers in different ducts and acini were added and averaged. The averaged percentages of tumor suppressor expressing cells in morphologically similar tissue components of PABC and non-PABC were statistically compared with the Pearson\'s Chi-squared test. The proliferation indexes in morphologically similar ducts or acini with and without aberrant p63 and WT-1 expression were similarly compared. Statistical significance was defined as the p-value \< 0.05.

Results
=======

Distinct immunoreactivities to calponin, p63, maspin, and WT-1 were elusively or preferentially seen in myoepithelial cells. WT-1, however, was also seen in endothelial cells and duct and acinar lumen. The negative controls were devoid of immunoreactivities to any of these molecules. Immunoreactivities to calponin, maspin, and WT-1 were predominantly seen in the cytoplasm. Immunoreactivities to Ki-67, ER, and PR were seen exclusively in the nuclei. Immunoreactivities to p63 were predominantly seen in the nuclei, but also seen in the epithelial cells of some cases (see below). Immunoreactivities to cytokeratin 5, 14, and 17 were exclusively present in the cytoplasm of myoepithelial cells.

In reduction mammoplasties and the morphologically clear-cut normal tissue component of both PABC and non-PABC, epithelial and myoepithelial cells were roughly equal in number, and all or nearly all the myoepithelial cells were similar in shape and size. Over 90% of morphologically distinct myoepithelial cells were uniformly immunoreactive to the myoepithelial cell phenotypic marker calponin, and about 90% of calponin positive myoepithelial cells co-expressed maspin, WT-1, and p63 (Fig. [1](#F1){ref-type="fig"}).

In hyperplastic and *in situ*malignant tissue components of non-PABC, the relative number of myoepithelial cells was significantly fewer than that of epithelial cells, and the shape and size of myoepithelial cells varied substantially. Over 90% of morphologically distinct myoepithelial cells, however, were uniformly and strongly immunoreactive to calponin immunostaining. Some ducts with malignant or hyperplastic lesions, however, harbored morphologically distinct myoepithelial cells that were strongly immunoreactive to calponin, whereas lacked the expression of p63 and WT-1 (Fig. [2](#F2){ref-type="fig"}).

In hyperplastic and *in situ*malignant components of PABC, the overall pattern of myoepithelial cell alterations and tumor suppressor expression was similar to that of non-PABC in all ducts encountered. PABC, however, displayed several unique properties that were not seen in their non-PABC counterparts:

1. Significantly fewer dusts encountered
----------------------------------------

In all 20 cases, normal or pathologically altered ducts accounted for only about 10% of the total epithelial cell population. Most ducts were distributed in the inter-lobular space.

2. Significantly decreased p63 and WT-1 expression in acini and terminal duct and lobular units (TDLU)
------------------------------------------------------------------------------------------------------

In sets of four immediate consecutive sections, calponin and maspin were uniformly expressed in all or nearly all morphologically distinct myoepithelial cells (Fig. [3](#F3){ref-type="fig"}a-[3](#F3){ref-type="fig"}b). In sharp contrast, in about 80% of the acini and TDLU, only about 10% and 30% of calponin positive myoepithelial cells showed WT-1 and p63 expression, respectively (Figs. [3](#F3){ref-type="fig"}-[4](#F4){ref-type="fig"}; Table [1](#T1){ref-type="table"}). Under high magnification, all or nearly all acini and TDLU with reduced p63 and WT-1 expression showed fragmentations or small focal disruptions in the surrounding myoepithelial cell layers. In about 20% of the acini and TDLU, however, all or nearly all morphologically distinct myoepithelial cells uniformly expressed all four markers. These acini and TDLU were arranged as morphologically distinct lobules with variable sizes. These lobules were generally separated by stromal tissues from adjacent lobules that showed significantly reduced p63 and WT-1 expression (data not shown).

3. Cytoplasmic p63 expression in the entire epithelial cell population of some lobules
--------------------------------------------------------------------------------------

In 8 (40%) cases, distinct cytoplasmic p63 expression was seen in a subset of epithelial cells. The number of cells with cytoplasmic p63 expression among cases varied significantly, from a few acinar clusters to over 30% of the entire epithelial cell population. These normal or hyperplastic p63 expressing cells were arranged as lobules, in which all or nearly all the epithelial cells uniformly expressed high levels of p63, in sharp contrast to adjacent normal ducts, which showed distinct nuclear p63 expression (Fig. [5](#F5){ref-type="fig"}). These cytoplasmic p63 expressing cells were often adjacent and cytologically similar to invasive cancer cells, which also showed distinct cytoplasmic p63 expression (Figs. [5](#F5){ref-type="fig"}g-[5](#F5){ref-type="fig"}h).

4. Increasing WT-1 expression in micro-vessels of the malignant tissue component
--------------------------------------------------------------------------------

In normal and hyperplastic tissue components, most micro-vessels showed no distinct or very weak. WT-1 expression. In the malignant tissue component, however, all or nearly all morphologically identifiable micro-vessels were strongly immunoreactive to WT-1 (Fig. [6](#F6){ref-type="fig"}). The expression of WT-1 in vascular structures was confirmed by different immuno-detection systems with different chromogens (Fig. [6](#F6){ref-type="fig"}), and also by immunohistochemistry with endothelial cell specific markers CD31 (data not shown).

5. Significantly elevated epithelial cell proliferation
-------------------------------------------------------

In sections double immunostained with myoepithelial cell and proliferation markers, a vast majority of the proliferating cells were seen in acinar clusters with focally disrupted myoepithelial cell layers, which consistently showed aberrant p63 or WT-1 expression. The size of these acinar clusters varied substantially and all these clusters showed a distinct boundary with their adjacent counterparts (Fig [7](#F7){ref-type="fig"}a-[7](#F7){ref-type="fig"}b). A vast majority of these acinar clusters were immediately adjacent to invasive cancers (Fig.[7](#F7){ref-type="fig"}c-[7](#F7){ref-type="fig"}h).

6. Significantly reduced ER and PR expression
---------------------------------------------

In non-PABC, about 50% of the acinar and duct cells in over 80% of the cases showed distinct ER or PR expression (data not shown). In sharp contrast, all cells in TDLU and acini with aberrant p63 and WT-1 expression lacked distinct ER or PR expression in all cases (data not shown).

The significant reduction of p63 and WT-1 expression in calponin positive myoepithelial cells of PABC was confirmed by immunohistochemistry for CK 5, 14, and 17. In sets of four immediate adjacent sections, all or nearly all morphologically distinct myoepithelial cells were uniformly immunoreactive to CK 5, 14, and 17, but only about 10% and 30% of CK positive cells showed WT-1 and p63 expression, respectively (Fig [8](#F8){ref-type="fig"}).

Discussion and Conclusions
==========================

The overall expression pattern of tumor suppressors in myoepithelial cells and biological presentations in epithelial cells seen in our current study are in total agreement with previous reports that the expression of p63 and WT-1 is inversely correlated with breast tumor progression and invasion [@B5]-[@B9]. Our findings of WT-1 expression in the vascular structure are in agreement with a recent study, which reported that "Endothelial WT1 expression was detected 95% of 113 tumors of different origin" [@B25]. To our best knowledge, our findings of the absence of p63 and WT-1 expression in a vast majority of the myoepithelial cells of acini and TDLU, cytoplasmic localization of p63 in the entire epithelial cell population of some lobules, increasing WT-1 expression in vascular structures of the invasive tissue component, and substantially different p63 and WT-1 expression between ducts and acini or TDLU, in PABC, however, have not been previously reported.

The absence of p63 and WT-1 expression in most myoepithelial cells in acini and TDLU of PABC is likely to result from two correlated mechanisms: (A) *Genetic defects in myoepithelial cell self-renewal-related genes*. As both p63 and WT-1 play significant roles in the early developmental of several organs and systems [@B27]-[@B29], it is possible that at the early stage of breast morphogenesis, the breasts of these patients may have exposed to certain external or internal insults that may have caused permanent damages in DNA structures of some primitive stem cells. These DNA structural damages resulted in the inactivation of, or defects in, myoepithelial cell renewal-related genes, which impaired the myoepithelial cell replenishment process to replace the aged or injured myoepithelial cells, resulting in a "senesced" myoepithelial cell population with significantly reduced p63 and WT-1 expression. Consistent with this possibility is the fact that the expression of maspin, a tumor suppressor that is not involved in early development [@B6], is not affected in all PABC cases in this study. (B) *Simultaneous activation and proliferation of multiple tumor stem cells.*The DNA structural damages may have also caused the inactivation of, or defects in, cell cycle control-and apoptosis-related genes in the epithelial cell population, which allow these cells to proliferate to form different acinar clusters or TDLU with the same genetic defects. These acinar clusters or TDLU may progress rapidly after external or internal insults, leading to the early occurrence of breast cancer at young ages. On the other hand, these clusters may become maturation-arrested after a few cycles of cells divisions, but remain the potential for unlimited proliferation and multi-lineage differentiation. During the last few weeks of pregnancy, these clusters are activated and simultaneously proliferating in responding to a sharp increase of estrogen, progesterone, and other hormones [@B21]-[@B23]. As the myoepithelial cell population lacks the receptors for these hormones, it may not be able to undergo vigorous proliferations to match the dramatic increase of epithelial cells, which could result in the over-stretch or even focal disruptions of the myoepithelial cell layers. Consistent with this possibility is the following facts: (1) the proliferation index is significantly higher in acini and TDLU with aberrant p63 and WT-1 expression, (2) the morphological and immunohistochemical profiles differ substantially among lobules, and (3) the entire cell population of some morphologically normal appearing lobules shared the same malignant cytological features and proliferation index with their adjacent invasive counterparts (as shown in Fig [7](#F7){ref-type="fig"}). This possibility is also supported by recent studies in human prostate tumors, which detected a DNA phenotype that is identical to that of invasive cancer in some "healthy" men, and in morphologically normal prostate tissues adjacent to prostate cancer [@B30]-[@B33].

Cytoplasmic p63 expression in the entire epithelial cell population of some lobules is likely to results from aberrant transportation of the p63 protein. Similar to the p53 protein, p63 is synthesized in the cytoplasm and constantly transported through the nuclear pore complex into the nuclei [@B34]-[@B35]. A number of factors, including alterations of the elements and molecules involved in p63 nucleo-cytoplasmic transportation could significantly impact the p63 cellular trafficking, and consequently alter its sub-cellular localization [@B34]-[@B35]. A previous study from our lab showed that only cells exhibiting secretory changes or secretory carcinomas had cytoplasmic p63 expression [@B36]. It is possible that the secretory products in PABC may form protein-protein complexes with p63, which prevent the import of p63 protein into the nuclei. Consistent with this possibility is the fact that some proteins could form protein-protein complexes with p53, which results in accumulation of p53 in the cytoplasm [@B37]-[@B38]. Although the clinical significance of cytoplasmic p63 expression in human breast is unknown, a similar morphological and immunohistochemical profile between cytoplasmic p63 expressing hyperplastic and adjacent invasive cancer cells (as shown in Figs. [5](#F5){ref-type="fig"}g-[5](#F5){ref-type="fig"}h) suggests the possibility of direct transformation of hyperplastic cells to invasive lesions. Consistent with this possibility are the facts that cutoplasmic localization of p63 is associated with poor patient survival in lung cancer and is also associated with tumor grade in meningiomas [@B39]-[@B40].

The differential WT-1 expression in myoepithelial and endothelial cells of the same case could potentially result from focal degeneration of aged or injured myoepithelial cells and the resultant auto-immunoreactions for the following reasons. *First,*myoepithelial cells belong to a self-renewal population that has to consistently proliferate and differentiate to replace the aged and injured myoepithelial cells. Any internal and external insults that impair the replenishment process could result in a "senesced" myoepithelial cell population that is morphologically distinct, whereas may loss the expression of tumor suppressors and other markers. *Second,* the degradation products of degenerated myoepithelial cells and the diffusible molecules secreted by the overlying tumor cells could function as self-epitopes to attract the infiltration of immunoreactive cells, resulting in localized chronic inflammation, which could directly incite angiogenesis or cause cellular and genomic damages [@B41]-[@B42]***.***WT-1 expression in endothelial cells could potentially result from or reflect the recapitulation of the early events of morphogenesis, which undergo extensive cell proliferation and vascularization. As the WT-1 encodes a transcription factor that binds to GC-rich sequences and regulates the expression of several genes of the growth factor family [@B43]-[@B47], it is likely that WT-1 might also regulate the expression of the vascular growth factor. Consistent with our speculation is the fact that the normal development and tumor invasion share the same mechanism for epithelial-branching and migration. It is also possible that, elevated WT-1 expression in endothelial cells may result from alternative splicing that results in an isoform of WT-1 mRNA, which has high affinity to bind to the vascular growth factor receptor. Consistent with our speculation is the fact that a recent study has shown that WT-1 17AA(-)/KTS isoform could induce morphological changes, and promotes cell migration and invasion in vitro, whereas other isoforms failed to induce similar changes under the same condition [@B48].

The specific cellular or molecular mechanism accounting for a potential correlation between tumor suppressor expression in myoepithelial cells and biological behavior in tumor cells is unknown, but is likely to result from the resultant consequences of aberrant tumor suppressor expression and focal disruptions in the myoepithelial cell layers. As the epithelium is normally devoid of both blood vessels and lymphatic ducts, and thus, totally relies on the stroma for its needed materials for normal functions and even survival, a focal myoepithelial cell layer disruption (FMCLD) could have several consequences, including (1) an increase of permeability for oxygen, nutrients, and growth factors, which selectively triggers the exit of stem or progenitor cells from quiescence [@B49]-[@B50], (2) the exposure of luminal cells to different cytokines, which facilitates vasculogenic mimicry and tumor angiogenesis [@B51]-[@B52], (3) The physical contact between luminal and stromal cells, which augments the expression of stromal MMP and facilitates epithelial-mesenchymal transition (EMT) and cell motility [@B53]-[@B54], and (4) The physical contact between luminal and immunoreactive cells, which directly cause genomic or cellular damages that trigger a cascade reaction of malignant transformation [@B41]-[@B42]. These alterations could individually or collectively trigger elevated proliferation in acinar clusters with aberrant tumor suppressor expression or with focally disrupted myoepithelial cell layers, which leads to the enlargement of FMCLD and stretched-out of the residual myoepithelial cells. Eventually, the entire epithelial cell population in these clusters completely loses their surrounding structures and transform directly to a new microenvironment that favors epithelial- mesenchymal transition and cell motility. Although these cells might not possess all the properties of invasive cancer cells, the changed microenvironment may act as the second "hit" to trigger a cascade reaction of malignant transformation [@B22]-[@B23]. As some of those acinar clusters with focally disrupted myoepithelial cell layers may represent a population of mutation-arrested stem cells and retain the potential for unlimited proliferation and multi-lineage differentiation, they may rapidly progress to invasive or metastatic breast lesions. In addition, hyperplastic acinar cells with cytoplasmic p63 expression may directly transform into invasive lesions.

No definite conclusions, however, could be drawn at present, since our sample size is small, and the clinical follow-up data are not available. On the other hand, if confirmed by further studies, our findings are likely to have several significant scientific and clinical implications. First, as a vast majority of the breast malignancies are originated from TDLU, the development of more applicable methods to quantitatively assess the expression of p63 and WT-1 expression in this site may be more effective than calponin immunostaining for early detection of breast cancer. Second, the elucidation of the mechanism of cytoplasmic p63 expression may lead to the development of new therapeutic agents to target cancer-related molecules in the cytoplasm or nuclei. Third, the development of different agents to target WT-1 in endothelial cells may have significant therapeutic value. Fourth, the development therapeutic agent to stimulate myoepithelial cell self-renewal or to prevent myoepithelial cell degradation may be more effective than the traditional approaches for breast cancer intervention and prevention.
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![Calponin and tumor suppressor expression in reduction mammoplasties. A set of four adjacent sections were immunostained for calponin and mapin, p63, and WT-1. Arrows identify myoepithelial cell layers. Note that about 90% of the myoepithelial cells in a small lobule are positive for calponin, and also co-express maspin, p63, and WT-1. a, c, e, and g: 100X; b, d, f, and h: a higher (300X) magnification of a, c, e, and g, respectively.](ijbsv05p0082g01){#F1}

![Lack of p63 and WT-1 in calponin positive myoepithelial cells A set of four adjacent sections were immunostained for calponin and mapin, p63, and WT-1. Arrows identify myoepithelial cell layers. Note that in a hyperplastic duct, a number of myoepithelial cells lack p63 and WT-1 expression, whereas they are positive for calponin and maspin. a, c, e, and g: 100X; b, d, f, and h: a higher (400X) magnification of a, c, e, and g, respectively.](ijbsv05p0082g02){#F2}

![Reduced p63 and WT-1 expression in calponin and maspin positive myoepithelial cells of PABC. Two sets of four adjacent sections were immunostained for calponin and mapin, p63, and WT-1. Asterisks identify normal ducts in the inter-lobular space. Arrows identify myoepithelial cell layers. Note that a vast majority of the myoepithelial cells in normal ducts are positive for all four markers, whereas a vast majority of the myoepithelial cells in the acini lack p63 and WT-1 expression. 200X.](ijbsv05p0082g03){#F3}

![Reduced p63 and WT-1 expression in calponin and maspin positive myoepithelial cells of PABC. Two sets of four adjacent sections were immunostained for calponin and mapin, p63, and WT-1. Asterisks identify normal ducts in the inttra-lobular space. Arrows identify myoepithelial cell layers. Note that a vast majority of the myoepithelial cells in normal ducts are positive for all four markers, whereas a vast majority of the myoepithelial cells in the acini lack p63 and WT-1 expression. 200X.](ijbsv05p0082g04){#F4}

![Cytoplasmic p63 expression in epithelial cells of PABC. Four sections from four different cases were immunostained for p63. Arrows identify myoepithelial cells with nuclear p63 localization in normal ducts. Note that the epithelial cells in some acinar clusters or the entire lobule show cytoplasmic p63 expression. In addition, some lobules with hyperplastic cells that show cytoplasmic p63 expression are immediately adjacent to, and share a similar morphological and immunohistochemical profile with, invasive cancer cells (g-h) a, c, e, and g: 100X; b, d, f, and h: a higher (400X) magnification of a, c, e, and g, respectively.](ijbsv05p0082g05){#F5}

![Increased cell proliferation in normal appearing epithelial cells near invasive lesions of PABC. Four sections from four different cases were double immunostained for calponin and Ki-67. N: normal; C: invasive cancer. Note that some morphologically normal appearing acinar clusters in the inter-lobular space or near the invasive cancer show substantially higher cell proliferation than their counterparts distant from the invasive lesion. a, c, e, and g: 80X; b, d, f, and h: a higher (200) magnification of a, c, e, and g, respectively.](ijbsv05p0082g06){#F6}

![Increased WT-1 expression in invasive lesions of PABC. Four sections from four different cases were double immunostained for WT-1. N: normal; C: invasive cancer. Note that the invasive tissue component has substantially more small vessels with WT-1 expression. a, c, e, and g: 80X; b, d, f, and h: a higher (200) magnification of a, c, e, and g, respectively.](ijbsv05p0082g07){#F7}

![Reduced p63 and WT-1 expression in cytokeratin positive myoepithelial cells of PABC. Two sets of four adjacent sections from two different cases were immunostained for CK 5, CK 14, p63, and WT-1, respectively. Arrows identify myoepithelial cells in normal ducts with expression of different markers. Note that all or nearly all morphologically distinct myoepithelial cells express CK 5 and CK 14, while a vast majority of the CK-positive cells lack p63 and WT-1 expression. 200X.](ijbsv05p0082g08){#F8}

###### 

Comparison of tumor suppressor expression in myoepithelial cells of PABC and non-PABC

  Tissue Type      Calponin (+) ME cells   With Maspin (%)   With p63 ((%)   With WT-1 (%)   p
  ---------------- ----------------------- ----------------- --------------- --------------- --------
  Non-PABC ducts   5,000                   4,637 (92.7%)     4,582 (91.6%)   4,512 (90.2%)   
  Acini or TDLU    5,000                   4,201 (84.0%)     4,120 (82.4%)   4,034 (80.1%)   \>0.05
  PABC ducts       2,000                   1,806 (90.3%)     1,796 (89.8%)   1,724 (86.2%)   
  Acini or TDLU    5,000                   4,015 (80.3%)     1,560 (31.2%)   541 (10.8%)     \<0.01
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